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ORIGINAL ARTICLE
Basic Study
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Abstract
AIM: To investigate the ability of a Prunella vulgaris
(P. vulgaris ) ethanolic extract to attenuate spontaneous
-/typhlocolitis in mdr1a mice.

Institutional animal care and use committee statement: All
studies involving were live vertebrate animals were approved by
the Iowa State University IACUC prior to use.

METHODS: Vehicle (5% ethanol) or P. vulgaris ethano
lic extract (2.4 mg/d) were administered daily by oral
-/WT
gavage to mdr1a or wild type FVB mice from 6 wk of
age up to 20 wk of age. Clinical signs of disease were
noted by monitoring weight loss. Mice experiencing
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spontaneous colitis in mdr1a -/- mice. World J Gastrointest
Pharmacol Ther 2015; 6(4): 223-237 Available from: URL:
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weight loss in excess of 15% were removed from the
study. At the time mice were removed from the study,
blood and colon tissue were collected for analyses that
included histological evaluation of lesions, inflammatory
cytokine levels, and myeloperoxidase activity.
RESULTS: Administration of P. vulgaris extracts to
-/mdr1a mice delayed onset of colitis and reduced
severity of mucosal inflammation when compared to
-/vehicle-treated mdr1a mice. Oral administration of the
P. vulgaris extract resulted in reduced (P < 0.05) serum
levels of IL-10 (4.6 ± 2 vs 19.4 ± 4), CXCL9 (1319.0
± 277 vs 3901.0 ± 858), and TNFα (9.9 ± 3 vs 14.8 ±
1) as well as reduced gene expression by more than
two-fold for Ccl2, Ccl20, Cxcl1, Cxcl9, IL-1 α, Mmp10,
VCAM-1, ICAM, IL-2, and TNFα in the colonic mucosa
-/-/of mdr1a mice compared to vehicle-treated mdr1a
mice. Histologically, several microscopic parameters
-/were reduced (P < 0.05) in P. vulgaris -treated mdr1a
mice, as was myeloperoxidase activity in the colon
(2.49 ± 0.16 vs 3.36 ± 0.06, P < 0.05). The numbers
+
of CD4 T cells (2031.9 ± 412.1 vs 5054.5 ± 809.5)
and germinal center B cells (2749.6 ± 473.7 vs 4934.0
± 645.9) observed in the cecal tonsils of P. vulgaris -/treated mdr1a were significantly reduced (P < 0.05)
-/from vehicle-treated mdr1a mice. Vehicle-treated
-/mdr1a mice were found to produce serum antibodies
to antigens derived from members of the intestinal
microbiota, indicative of severe colitis and a loss of
adaptive tolerance to the members of the microbiota.
These serum antibodies were greatly reduced or absent
-/in P. vulgaris -treated mdr1a mice.

INTRODUCTION
The intestinal epithelium is the interface between the
host and the lumen of the gastrointestinal tract and
cooperates with other innate immune mechanisms to
protect the host from microbial-induced inflammation as
well as to hinder colonization and invasion by intestinal
microorganisms. The ability to maintain low levels
of mucosal inflammation in the gut is believed to be
important for mucosal homeostasis. However, in the
context of inflammatory bowel diseases (IBD), such
as Crohn’s disease (CD) and ulcerative colitis (UC),
regulation of intestinal inflammation often fails resulting
[1]
in mucosal damage and chronic disease . While
idiopathic in nature, current hypotheses regarding the
etiology of IBD point to complex multifactorial causalities,
which include disruption of the intestinal epithelial barrier,
dysbiosis of the microbiota, genetic predispositions,
chronically activated inflammatory immune cells, and
[2,3]
failed adaptive immune regulatory responses .
Much IBD research has focused on aberrant adap
tive immune responses to antigens derived from
the microbiota. More emphasis is now being placed
on elucidating the role innate immune cells (e.g.,
neutrophils), cytokines, chemokines, and their related
transcription factors play in the initiation and/or
maintenance of epithelial damage as the initial step in
[4]
the onset of IBD . In the absence of effective epithelial
barrier function, compartmentalization that is meant
to separate immune cells in the lamina propria from
the numerous bacterial and food antigens normally
[5]
sequestered in the lumen is lost . A loss of epithelial
barrier integrity is characteristic of UC and CD, and
the consequential loss of immunologic tolerance to the
microbiota initiates a cascade of signaling pathways
that activate both innate and adaptive immune
[6]
mechanisms .
The most common therapies used for the treatment
of IBD are immune suppressive and anti-inflammatory
drugs and biologicals such as monoclonal antibodies
[7,8]
(e.g., anti-TNF) . Metronidazole and ciprofloxacin have
also been utilized in several clinical trials related to the
treatment of UC, CD, and pouchitis with underwhelming
[9]
results . Immunosuppressive therapies include
monoclonal antibodies against TNF-α, 5-aminosalicylates
[10-12]
. For many of these treatments,
(5-ASA), and steroids
there is the potential for adverse effects that may include
increased susceptibility to bacterial and viral infections
and increased risk of cancer. One study showed that IBD
related hospitalizations at high volume IBD treatment
centers around the United States increased 6-fold

CONCLUSION: The anti-inflammatory activity of P.
vulgaris ethanolic extract effectively attenuated the
-/-

severity of intestinal inflammation in mdr1a mice.

Key words: Prunella vulgaris ; Spontaneous colitis;
Inflammatory bowel disease; Mdr1a; Botanical extract;
Mucosal inflammation; Nutraceutical
© The Author(s) 2015. Published by Baishideng Publishing
Group Inc. All rights reserved.

Core tip: Extracts of Prunella vulgaris (P. vulgaris )
contain multiple anti-inflammatory phenolics and
flavonoids and we report that oral administration of an
ethanolic extract of P. vulgaris ameliorated the severity
-/of spontaneous colitis in 20 wk old mdr1a mice.
Because these mice are genetically prone to develop
colitis by 10 wk of age, daily oral treatments were
initiated at 6 wk of age. This treatment regimen resulted
in the inhibition of multiple parameters of inflammation
that collectively contributed to ameliorate the severity of
mucosal inflammation suggesting that botanical extracts
may be used as effective complementary intervention
strategies for the treatment of colitis.
Haarberg KMK, Wymore Brand MJ, Overstreet AMC, Hauck
CC, Murphy PA, Hostetter JM, Ramer-Tait AE, Wannemuehler
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[13]

at a final plant extract concentration of 12 mg/mL. The
working P. vulgaris extract was divided into 2 mL aliquots
and stored at -20 ℃ until use. P. vulgaris extracts from
North Central Regional Plant Introduction Station were
screened for endotoxin by using the Limulus Amebocyte
Lysate Test (BioWhittaker, Inc., Walkersville, MD)
according to manufacturers’ specifications, and there
was no detectable endotoxin present in the extract
(data not shown). Extracts were tested for antimicrobial
activity in vitro with no activity demonstrated.

from 1998 to 2004 . This data illustrates that despite
advances in IBD research, current therapies have not
decreased the frequency of IBD related hospitalizations
and surgical interventions are still common for severe
forms of IBD. These facts and the financial burdens
associated with expensive therapeutic regimens have
lead patients to explore unconventional means of coping
with IBD.
A 1998 study showed that up to 51% of surveyed
IBD patients had used alternative or complementary
therapies and, in particular, 16% of patients used the
[14]
alternative therapies specifically for their IBD . For
most complementary therapies (e.g., nutraceuticals),
many anecdotal claims of health benefits exist with very
little scientific data to support or negate those claims.
Prunella vulgaris (P. vulgarisis) commonly used in
traditional Chinese medicine for wound healing, indiges
tion, burns and anti-inflammatory therapy. P. vulgaris
contains several bioactive phenolics, triterpenoids and
[15]
flavonoids . Dietary phenolics such as rosmarinic acid,
ursolic acid, and caffeic acid are all found in extracts of
P. vulgaris, and have been shown to possess antioxi
[16-21]
dant, anti-inflammatory and anti-cancer activities
.
Caffeic acid has also been shown to ef)fectively
attenuate chemically induced experimental colitis
[22]
through upregulation of cytochrome P450 (CYP4B1) .
Flavonoids, like those found in P. vulgaris, have been
[23]
implicated as potential therapeutics for IBD as well . In
contrast to its ability to attenuate DSS-induced colitis, the
flavonoid luteolin was found to attenuate spontaneous
colitis by inhibiting the activation of NF-κB. Despite this
promising evidence, there are no published reports
evaluating the use of P. vulgaris extracts as a treatment
for IBD. In this context, we have designed this study to
test the hypothesis that an ethanolic extract of P. vulgaris
will decrease gastrointestinal mucosal inflammation and
thereby ameliorate the severity of spontaneous colitis in
-/mdr1a mice.

Animals

Prior to the initiation of any work being performed,
all animal related experiments were approved by the
Institutional Animal Care and Use Committee (IACUC) at
Iowa State University. Incumbent with IACUC approval,
methods and procedures were used tomimimize pain
and/or distress of all animals used in this study. Four
-/to five week old male mdr1a FVB.129P2-Abcb1a
tm1BorN7 and wild type (WT) FVB.129P2 mice were
obtained from Taconic Farms, Inc. (Germantown, NY).
Animals were housed and maintained in the Laboratory
Animal Resource facility at the College of Veterinary
Medicine, Iowa State University. Established specific
pathogen-free husbandry practices were followed, and
twelve-hour light/dark cycles were applied. Upon arrival
and throughout the study, mice were fed a defined
Harlan Teklad AIN93 (M) rodent chow (Madison, WI) to
control the amount of phytochemicals in their diet.

Experimental design

MATERIALS AND METHODS
Prunella vulgaris extract preparation

Information about the specific provenance of P.
vulgaris accession Ames 27664, obtained from Dr. Mark
Wiederlichner at the USDA-ARS North Central Regional
Plant Introduction Station (Ames, IA), is available on the
Germplasm Resources Information Network database
at http://www.ars-grin.gov/npgs/acc/acc_queries.html.
Above ground portions of plants from P. vulgaris (Ames
27664), harvested in 2008 were prepared for storage
by drying for 8 d at 38 ℃ in a forced-air dryer with
constant humidity. The dried material was ground with
a 40-mesh screen and stored at -20 ℃ under N2 until
extraction. Weighed plant material was extracted with
95 ethanol with Soxhlet extractors for 6 h. The extract
was concentrated by rotary evaporation at < 30 ℃ and
lyophilized. The residue weight was recorded and the
residues stored at -20 ℃ until solubilized in a final
working solution of 5% ethanol in sterile distilled water

WJGPT|www.wjgnet.com

-/-

Three treatment groups of mice where utilized: Mdr1a
mice that were orally gavaged with 2.4 mg/d P. vulgaris
extract in a 200 µL volume (prepared as described
-/WT
above) and mdr1a and FVB mice were orally
gavaged with 5% ethanol vehicle alone; there were 4 to
10 mice/group per experiment. Gavage was performed
using a 20 gauge feeding needle once daily beginning
at 6 wk of age until the mice reached 20 wk of age or
were removed from the study because of severe clinical
wasting and/or weight loss exceeding 15% of their peak
body weight in order to minimize pain and discomfort.
At necropsy, mice were euthanized by CO2 asphyxiation.
Following euthanasia, blood was collected by cardiac
puncture and separate sections of each cecum and
proximal colon were excised, washed, and stored for
further histological, myeloperoxidase (MPO) enzymatic
and real-time PCR analysis. Serum was analyzed by
multiplex assay to measure cytokine and chemokine
levels as well as western blot analysis for antibody
reactivity to antigens derived from selected members
of the microbiota. Cecal tonsils were also collected for
flow cytometric analysis of T and B cell populations.
All results are representative of two independent
experiments.

Macroscopic typhlocolitis assessment

Following euthanization, the colon and cecum were
excised, photographed, measured and scored for
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severity of macroscopic lesions. Gross typhlocolitic
lesions were scored using a 9-point additive scale: A
score of zero being a healthy animal and a score of 9
being a maximally diseased animal. Score parameters
evaluated included: (1) cecal atrophy; (2) enlarged
cecal tonsil or other enlarged lymphoid aggregates;
(3) emptying of cecal contents; (4) abnormally watery
or mucoid intraluminal cecal and/or colonic contents;
(5) bloody cecal contents; (6) bloody colonic contents;
(7) visible thickening and rigidity of the cecum; (8)
presence of visible thickening and rigidity of the colon;
and (9) absence of formed fecal pellets in the colon. In
accordance with approved IACUC protocol, mice that
developed severe colitis prior to 20 wk of age were
removed from study when they lost ≥ 15% of their
maximal body weight. Mice were also removed from the
study within 5 d of the onset of persistent clinical signs
of disease as characterized by bloody stools, diarrhea,
ruffled fur, and hunched gate.

study, was euthanized by CO2 asphyxiation, and 500 µL
to 1 mL of blood was immediately collected by cardiac
puncture with a heparinized needle (heparin at 5000
USP heparin units/0.5 mL is drawn into the needle and
syringe and then expelled to coat the inside of the needle
with heparin). The heparinized blood was centrifuged at
250 x g for 10 min, the supernatant discarded and the
red blood cells (RBC) lysed. In brief, 1 mL of ACK lysis
buffer (8042 mg/L ammonium chloride, 1001 mg/L
potassium bicarbonate, 3.722 mg/L ethylene diamine
tetraacetic acid disodium, pH 7.2) was added to the
pellet, vortexed gently for 1 min, 1 mL of PBS was added,
and the mixture was centrifuged for 10 min at 250 x g.
The lysis was repeated until the pellet was white and the
supernatant was clear. Following RBC lysis, the pellet was
resuspended in 1 mL of PBS/PMSF (0.1 mmol/L), cell
numbers were enumerated using a cell counter (average
6
yield of 3 x 10 cells/mL) and the cells were sonicated
at an amplitude of 5, pulse on for 4 s, pulse off for 1 s,
for 20 s total. The sonicated tissue samples were then
centrifuged at 250 x g for 15 min and the supernatant
stored at 4 ℃ until the tissue samples were prepared.
Frozen proximal colonic sections were thawed, blotted
to remove as much excess fluid as possible, trimmed
to roughly 35 mg and their weights recorded. Tissues
were then homogenized for 1 min at maximum power
in 1 mL PBS/PMSF (0.1 mmol/L) and the homogenizer
probe was washed 5 times with PBS between tissue
samples. Homogenate cell counts were recorded, and
each sample was then sonicated as described above.
The tissue sonicates were then centrifuged at 250 x
g for 15 min, the supernatant collected and the pellet
discarded. Each lysate prepared from tissue or peripheral
blood monocytes (PBMC) was analyzed for total protein
using a NanoDrop ND-1000 UV-Vis Spectrophotometer
(NanoDrop Technologies Inc., Wilmington, DE). Individual
lysates were pipetted into 96-well, flat bottom microtiter
plates. The PBMC lysates (150 µL/well) were serially
diluted (10, two-fold dilutions) and analyzed in triplicate
wells. For each tissue lysate, 150 µL was pipetted into
separate wells and analyzed in triplicate. To each well,
50 µL of 0.78 mg/mL 3,3,5,5-tetramethylbenzidine
dihydrochloride hydrate was added, followed immediately
by the addition of 50 µL hydrogen peroxide (H2O2) (5
mmol/L). The reaction was allowed to proceed for 2
min (wells turned bright blue), followed by the addition
of 50 µL of sulfuric acid (1 mol/L) to stop the reaction.
The optical density (OD) was measured at 405 nm
spectrophotometerically (V-Max, Molecular Devices,
United States) using SOFTmax PRO 4.0 software. The
MPO content was determined by comparison to the
standard curve and MPO activity was expressed as the
relative units of enzyme activity per gram of wet weight
of tissue.

Histopathological assessment

Sections of excised cecum and proximal colon were
placed in 10% buffered formalin overnight, paraffin
embedded, sectioned, and routinely stained with
hematoxylin and eosin. Stained colonic and cecal
sections were scored by a board-certified veterinary
pathologist, Dr. Jesse Hostetter of Iowa State University
(Ames, IA), blinded to the treatments as previously
[24,25]
described
. Microscopic mucosal lesion scores were
assessed by five parameters, with each parameter
scored on a scale of 0-5 (5 = maximum severity).
Score parameters include: (1) ulceration of the mucosa;
extent of inflammatory cell infiltrate; (2) mucosal
edema characterized by the extent of lymphatic and
vascular distortion and expansion of the mucosa/
submucosa by clear space; (3) stromal collapse and
necrosis of the glands; and (4) glandular hyperplasia
characterized by the crowding and immaturity of
enterocytes along the gland and gland dilation. In
addition to score, mucosal height was determined and
recorded as a ratio of gland height to gland width, and
the specific inflammatory cell populations, if present,
were recorded. Score parameters were considered
individually and as an additive histopathological score
with mucosal height included in the additive score.

Myeloperoxidase assay

MPO activity was assessed as a measure of neutrophil/
granulocyte accumulation in proximal colonic tissues.
The MPO assay was performed as previously described
[22]
with several modifications . Proximal colon sections
collected at necropsy were gently flushed with PBS to
remove luminal contents and stored in 1 mL of freshly
prepared PBS supplemented with the protease inhibitor
phenylmethanesulfonyl fluoride (PMSF) at 0.1 mmol/L
and 15% dimethylsulphoxide (DMSO) at -20 ℃ for no
more than 7 d prior to assay. Samples used as positive
controls for MPO activity were prepared fresh the day the
WT
assay from peripheral blood. One FVB mouse, not on

WJGPT|www.wjgnet.com

Serum cytokine/chemokine quantification
-/-

WT

Following euthanasia of mdr1a and FVB mice, blood
was collected via cardiac puncture. The blood was
allowed to clot for 24 h at 4 ℃ after which samples were

226

November 6, 2015|Volume 6|Issue 4|

Haarberg KMK et al . Prunella vulgaris attenuates colitis
+

centrifuged at 10000 x g for 10 min. Serum was then
removed and stored at -20 ℃ until use. The day of assay,
serum samples were thawed to room temperature.
Concentrations of cytokines and chemokines of interest
were measured using the Millipore (Billerica, MA) mouse
cytokine-chemokine multiplexed assay kit. Analytes
screened include: Eotaxin, G-CSF, GM-CSF, IFN-γ, IL-10,
IL-12 (p40), IL-12 (p70), IL-13, IL-15, IL-17, IL-1α, IL1β, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-9, IP-10, KC,
LIF, LIX, M-CSF, MCP-1, MIG, MIP-1α, MIP-1β, MIP-2,
RANTES, TNF-α, and VEGF. The assay was performed
according to the manufacturer’s instructions. In brief,
supplied analyte standards (range: 10000 to 3.2 pg/mL),
quality control standard, and buffer only control samples
were analyzed in duplicate wells of the supplied 96 well
plate. Mouse serum samples were diluted 1:1 in supplied
assay buffer plated for each mouse. Supplied serum
matrix and supplied assay buffer were added to all wells.
Supplied pre-conjugated multiplex analyte beads were
added to each well and the samples were incubated at
4 ℃ overnight on a plate shaker (Barnstead International
Titer Plate Shaker, setting 5, Model No. 4625). Supplied
detection antibody was added to all wells and allowed
to incubate at room temperature while shaking for 2
h. Supplied streptavidin-phycoerythrin was incubated
for 30 min at room temperature while shaking. The
mean fluorescence intensity (MFI) was measured using
Luminex platform technology (The FlowMetric System,
Luminex, Austin, TX). MFIs were subsequently converted
to concentrations using a 5-parameter logistic or line
curve-fitting method in MasterPlex QT Software (MiraiBio
Group, San Francisco, CA).

PE-conjugated anti-rat IgG2a (eBioscience, San Diego,
CA). PNA has no isotype control. Analysis was performed
using a BD FACSCanto flow cytometer (BD, San Jose,
CA) made available through the Flow Cytometry Core
Facility at Iowa State University (Ames, IA). Data analysis
was performed using FlowJo software (TreeStar Inc.,
Ashland, OR).

Western blot analysis
-/-

Flow cytometric analysis of cecal tonsil cell populations
-/-

WT

Cecal tonsils from mdr1a and FVB mice were excised,
placed in complete cell culture medium (10 mL heatinactivated FBS, 1 mL penicillin/streptomycin, 1 mL
glutamine, 0.1 mL 50 mmol/L β-mercaptoethanol, 2.5
mL 1M Hepes buffer in 85.4 mL DMEM containing 4.5
g/L glucose and sodium pyruvate), and homogenized
mechanically on ice. Stainless steel wire strainers (60
mesh) were used to prepare single cell suspensions and
5
remove particulate matter. Cells (5 × 10 cells/tube)
were washed in FACS buffer, centrifuged at 250 x g
and incubated in FACS buffer containing 1:100 rat IgG
and fluorochrome labeled reagents for 15 min on ice.
Following labeling, cells were washed with FACS buffer,
centrifuged and fixed in 200 µL of BD stabilizing fixative.
Cellular preparations from individual mice were label
ed with the following fluorochrome-labeled reagents:
+
+ [26]
Germinal center B cells (PNA B220 )
identified
using FITC-conjugated PNA and Alexa 700-conjugated
+
anti-B220 mAb, CD4 T cells were identified using
+
PE-Cy7-conjugated anti-CD4 mAb and CD8 T cells
were identified using APC-conjugated anti-CD8β mAb.
The following isotype controls were utilized: Alexa
700-conjugated anti-rat IgG2aκ, PE-Cy7-conjugated
+
+
anti-rat IgG2a , APC-conjugated anti-rat IgG2b and

WJGPT|www.wjgnet.com

WT

Sera from mdr1a and FVB mice were used to evaluate
the presence of serum antibody against select members
of the intestinal microbiota. Whole cell sonicates (WCS)
of three members of the clostridial cluster group
XIVa (ASF356, ASF500, and ASF502) were cultivated
anaerobically, cells were harvested by centrifugation,
washed in PBS, lyophilized, and stored at -20 ℃ until
[27,28]
use
. Cells were then weighed and suspended in PBS
to 2 mg/mL. The resulting suspension was sonicated on
ice for 3 min at the following settings: Amplitude of 50 for
2, 30 s pulses with 5 s between each pulse; amplitude
75 for 2, 30 s pulses with 5 s between each pulse;
amplitude 100 for 2, 30 s pulses with 5 s between each
pulse. The sonicate was sterilized by UV light (six-minute
exposure) and sterility was confirmed bacteriologically.
For each preparation, protein content was determined
by bicinchoninic acid (BCA) analysis (Pierce Laboratories,
New Haven, Connecticut, United States), aliquoted
and stored at -20 ℃. Whole cell sonicates of ASF356,
ASF500, and ASF502 (8 µg of total protein content)
were subjected to SDS-PAGE using 12% tris-glycine
gels (BioRad, Hercules, CA) and transferred to PVDF
membranes. Each individual antigen was analyzed using
pooled anti-sera (1:250) from separate treatment groups
as described above The membranes were then reacted
with alkaline phosphatase (AP) conjugated anti-mouse
IgG (H+L) (1:1000, Southern Biotech, Birmingham,
AL) in a solution containing tris buffered saline (pH 7.6),
1% Tween 20 (TBST) and 2.5% non-fat, skim milk.
Immunoreactive proteins were visualized using Sigma
fast red tablets (Sigma, St. Louis, MO) according to
manufacturers’ instructions.

Pathway finder R2 profiler PCR array analysis

To evaluate the activation of signal transduction
pathways modulated by treatment with the P. vulgaris
extract, cecal gene expression was analyzed using
2
the RT profiler signal transduction pathway finder
PCR array from QIAGEN (Germantown, MD) as per
the manufacturer’s instructions. In brief, total RNA
was isolated from cecal tissue collected that had been
[29]
stored at -20 ℃ in RNAlater using the TRIzol method .
2
RNA was further purified using the RT qPCR-grade
RNA isolation kit from QIAGEN (Germantown, MD)
according to manufacturer’s instructions. RNA quality
(8.2 to 9.4) was assessed using an Agilent 2100
BioAnalyzer (Agilent Technologies, Palo Alto, CA). Prior
to preparation of cDNA, RNA samples were tested
by PCR using oligonucleotide primers for GAPDH to
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RESULTS

Percent survival

100

The ethanolic extract of P. vulgaris decreases severity
of macroscopic disease parameters and delays onset of
severe colitis in mdr1a-/- mice
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To determine the efficacy of P. vulgaris extract in the
-/WT
treatment of spontaneous colitis, mdr1a and FVB
mice were gavaged daily with vehicle (5% ethanol) or
2.4 mg P. vulgaris extract. Previously published data
-/shows that mdr1a mice develop disease between 8
and 36 wk of age, with the average age of disease onset
[30]
WT
occurring at 20 wk . As expected, FVB mice treated
with P. vulgaris were not adversely affected by the
administration of the extract despite the long course (14
wk) of treatment (data not shown). As anticipated, many
-/vehicle-treated mdr1a mice developed severe colitis
and weight loss and were removed from study prior
-/to 20 wk of age. Out of 16 mdr1a mice treated with
vehicle, 7 required removal from study prior to 20 wk
of age, compared to only 4 out of 13 P. vulgaris-treated
-/mdr1a mice. Treatment with the P. vulgaris extract
was able to delay onset of severe colitis and reduce
-/the number of mdr1a mice that had to be removed
from study, the difference was not significant when
-/compared to vehicle-treated mdr1a mice (Figure 1). In
addition, the phlogistic nature of the resident microbiota
-/contributes to the mucosal inflammation in mdr1a mice
as evidenced by the ability of metronidazole treatment
to prevent the onset of clinical disease (Figure 1).
Representative photographs (Figure 2) show the
extent of macroscopic and microscopic tissue damage in
-/vehicle-treated mdr1a mice. In these mice, ceca were
atrophied with visibly enlarged cecal tonsils suggesting
immune activation. The ceca of the vehicle-treated
-/mdr1a mice were almost devoid of contents, and both
cecal and colonic tissues are notably thickened and rigid.
Occasional blood was noted in cecal and colonic contents
while no formed fecal pellets were noted in the vehicle-/treated mdr1a mice. Conversely, the ceca and colons
-/of P. vulgaris-treated mdr1a mice were markedly
improved and more closely resembled the tissue
WT
appearance of healthy FVB as well as metronidazole-/treated mdr1a mice with regard to all parameters
assessed.
Macroscopically, mild to severe typhlocolitis (a
score of 2 to 9, respectively) was observed in 100% of
-/vehicle-treated mdr1a mice while all of the P. vulgaristreated mice presented with macroscopic scores below
-/the average score of the vehicle-treated mdr1a mice
(Figure 2C). P. vulgaris prophylaxis significantly (P <
0.05) improved macroscopic parameters of disease
-/when compared to vehicle treatment in mdr1a mice.
In addition, the median colon length for P. vulgaris-/treated mdr1a mice was longer than that for the
-/vehicle-treated in mdr1a mice indicating less severe
epithelial injury (Figure 2). Regardless of the treatment,
WT
FVB mice did not exhibit any signs of clinical disease
or tissue damage (Figure 2). These results indicate
that treatment with the P. vulgaris ethanolic extract

a

-/-

mdr1a vehicle
-/mdr1a metronidazole
-/mdr1a Prunella vulgaris
80

100

Days on study

Figure 1 Effect of treatment with a Prunella vulgaris ethanolic extract on
the onset of colitis in mdr1a-/- mice. Mdr1a-/- mice were removed from the
study as they developed severe clinical disease (e.g., > 15% weight loss) before
the termination of the experiment as described in Materials and Methods. aP <
0.05, as compared to FVBWT control mice. Vehicle-treated mdr1a-/- mice n = 16,
metronidazole-treated mdr1a-/- mice n = 10, Prunella vulgaris-treated mdr1a-/mice n = 13. This survival (i.e., mice remaining on study) curve is representative
of two independent experiments.

confirm the absence of genomic DNA contamination.
Invitrogen SYBR Green/ROX, primers and 1 µg of
isolated RNA from each mouse were subjected to the
following PCR conditions and were run on an ABI 5700
(Applied Biosystems Inc., Carlsbad, CA): 95 ℃ for 10
min, followed by 40 cycles of amplification (95 ℃ for
10 s, 60 ℃ for 15 s). All cycle threshold (CT) values
were greater than 30, and were acceptable for further
use (data not shown). GAPDH oligonucleotide primers
used were: 5'-TGTGTCCGTCGTGGATCTGA-3' and
5'-CCTGCTTCACCACCTTCTTGA-3'. RNA (1 µg) from each
2
mouse was then converted to cDNA using QIAGEN RT
First Strand kit according to manufacturers’ instructions.
Resulting cDNA from individual mice was pooled into
diseased and healthy groups of mice for each treatment
group and each experiment, mixed with the kit’s array
master mix experimental cocktail preparation, and
subjected to the same PCR conditions and equipment
noted above. PCR array data was analyzed using
2
QIAGEN RT PCR array analysis software and fold
changes were calculated relative to house-keeping
genes by the software. Only 2-fold changes or greater
were considered.

Statistical analysis

Following review by a biostatistician for appropriateness
of the statistical methods used, all data, except survival
curves, were evaluated by the Kruskal-Wallis test with
Dunn’s multiple comparisons test. Because the KruskalWallis test has no analog of the ANOVA linear contrast
that focuses attention on a specific pre-specified
-/comparison of groups, differences in the mdr1a groups
were further evaluated by the Mann-Whitney test for
ordinal data and unpaired t-test with Welch’s correction
for continuous data. Survival curves were evaluated by
the Log-rank (Mantel-Cox) test. A P-value of < 0.05 was
considered statistically significant. Prism 6 software was
used for all statistical calculations.
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Figure 2 Oral administration of a Prunella vulgaris extract attenuated both microscopic and macroscopic cecal lesions in mdr1a-/- mice. A: Representative
photographs of ceca and colons (left) and representative photomicrographs (200 ×) of histological sections of ceca (right) collected at necropsy from FVBWT or mdr1a-/mice treated with either vehicle or Prunella vulgaris (P. vulgaris) extract; B: Colon lengths were measured at necropsy and the group range is represented. Whiskers
indicate minimum and maximum values, while the horizontal line represents the group median; C: Macroscopic typhlocolitic scores were assigned at necropsy as
described in the Materials and Methods (Max/Severe = 9, Min/Healthy = 0). aP < 0.05, bP < 0.01 compared to mdr1a-/- vehicle as calculated by Kruskal-Wallis test.
Vehicle-treated FVBWT mice n = 6, vehicle-treated mdr1a-/- mice n = 16, P. vulgaris-treated mdr1a-/- mice n = 13.

Table 1 Histopathological scores of cecal tissue
Microscopic parameter
Mucosal height (μm)
Ulceration
Inflammation
Edema
Stromal collapse (necrosis)
Gland hyperplasia
Additive cecal score
Mice exhibiting cecal neutrophil infiltrate

FVB

WT

vehicle (n = 6)

-/-

-/-

mdr1a vehicle (n = 10)

mdr1a P. vulgaris (n = 7)

4.6 ± 0.2
1.9 ± 0.3
3.6 ± 0.2
2.4 ± 0.3
1.7 ± 0.4
2.8 ± 0.2
17.0 ± 1.2
100%

3.9 ± 0.2
1.2 ± 0.4
2.5 ± 0.4c
0.9 ± 0.3c
0.5 ± 0.4
2.1 ± 0.3c
11.1 ±1.5
38%c

a

3.5 ± 0.2
0.2 ± 0.2
1.3 ± 0.2b
0.7 ± 0.5a
0.0 ± 0.0a
1.2 ± 0.2b
6.9 ± 0.9b
17%b

Average values are shown here ± standard error of the mean except where noted. aP < 0.05, bP < 0.01 compared to mdr1a-/- vehicle with
Kruskal-Wallis test with Dunn’s multiple comparisons test. cP < 0.05 compared to mdr1a-/- vehicle with Mann-Whitney test.

attenuated macroscopic disease and delayed the onset
-/of spontaneous colitis in mdr1a mice.

and inflammatory cell infiltration, as well as submucosal
edema and occasional stromal collapse (Figure 2 and
-/Table 1). P. vulgaris-treated mdr1a mice exhibited
statistically significant (P < 0.05) improvement in
inflammation, edema, gland hyperplasia, and neutrophil
WT
infiltration (Table 1). As expected, FVB mice presented
with no evidence of mucosal inflammation. While 100%
-/of vehicle-treated mdr1a mice exhibited extensive
neutrophilic infiltration into the cecal lamina propria,
neutrophils were only noted in cecal mucosa of 38% of
-/P. vulgaris-treated mdr1a mice (Figure 2 and Table
1). As a measure of the infiltration of granulocytes

Impact of P. vulgaris treatment on the severity of
histopathological lesions

Histological inflammation of the cecum (Table 1) and
colon (data not shown) was evaluated in the context
of mucosal height, ulceration, extent and character of
inflammatory cell infiltrate, edema, stromal collapse
and glandular necrosis, and glandular hyperplasia. The
-/ceca of vehicle-treated mdr1a mice were characterized
by crypt hyperplasia, extensive transmural ulceration
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4

-/-

to vehicle-treated mdr1a mice. This data indicates
that oral administration of the ethanolic extract of P.
vulgaris is able to attenuate production of several innate
chemokines and cytokines induced by the inflammatory
-/response in mdr1a mice.

a

3
2
1
0

b

WT

FVB
vehicle

-/-

mdr1a
vehicle

Differential regulation of gene expression pathways by
in vivo treatment with the ethanolic extract of P. vulgaris

-/-

To further characterize the attenuation of mucosal
inflammation provided by P. vulgaris treatment, a
microarray analysis for inflammatory gene expression
was performed in order to identify differential gene
regulation between disease phenotypes of botanical
-/extract-treated mdr1a mice (e.g., healthy = macro
scopic score < 2 ; colitic = macroscopic score ≥ 2) and
WT
-/between FVB mice and mdr1a mice treated with
vehicle. At the extremes of microscopic and macroscopic
lesion scores, it was observed that no vehicle treated
-/mdr1a mice were characterized as “healthy” and no
WT
FVB mice were characterized as “colitic” (data not
shown). Genes encoding CCL2, CXCL1, CXCL9, IL1α, MMP10, TNF-α, VCAM-1, CCL20, and IL-2 were all
downregulated more than 2-fold by P. vulgaris treatment
-/in mdr1a mice that did not develop colitis (Table 3).
P. vulgaris treatment appears to modulate the NF-κB
pathway in the preservation of mucosal homeostasis in
-/mdr1a mice.

mdr1a

P. vulgaris

Figure 3 Administration of a Prunella vulgaris ethanolic extract reduced
local myeloperoxidase activity in the colon of mdr1a-/- mice. Homogenates
of colonic tissue were subjected to an assay for MPO activity. aP < 0.05, bP <
0.01 compared to mdr1a-/- vehicle as calculated by Kruskal-Wallis test. Vehicletreated FVBWT mice n = 6, vehicle-treated mdr1a-/- mice n = 10, P. vulgaristreated mdr1a-/- mice n = 7. MPO: Myeloperoxidase; P. vulgaris: Prunella
vulgaris.

into the mucosal tissue, MPO activity was assessed in
tissue homogenates. In comparison to tissue samples
-/from vehicle-treated mdr1a mice, the associated
MPO activity was significantly diminished in P. vulgaris-/treated mdr1a mice (P < 0.05) (Figure 3). In contrast
to colon length, there was no histological evidence
that the P. vulgaris treatment attenuated microscopic
-/lesions when compared to vehicle-treated mdr1a
mice (data not shown), suggesting that the bioactive
benefit of P. vulgaris localized in the cecum. Together,
these data indicated that the benefits provided by the
oral administration of P. vulgaris were to attenuate the
severity of inflammation and injury in the cecal mucosa
in association with a reduction of the presence or
recruitment of inflammatory granulocytes.

Influence of P. vulgaris on local T cell and B cell
populations

Because T and B cells are activated as a consequence
of inflammation, T cell and B cell populations in the
-/WT
cecal tonsils of mdr1a and FVB mice were analyzed
to evaluate the effects of P. vulgaris treatment on local
lymphocyte populations (Figure 4). Severe colitis in
-/vehicle-treated mdr1a mice resulted in 3-fold more
+
+
CD4 T cells (Figure 4A) and 6-fold more CD8 T cells
(Figure 4B) in the cecal tonsil as compared to vehicle
WT
-/gavaged FVB mice. In P. vulgaris-treated mdr1a
+
mice, the numbers of CD4 T cells in the cecal tonsils
were significantly lower (P < 0.05) when compared to
-/vehicle-treated mdr1a mice (Figure 4A), and there was
+
a trend indicating fewer CD8 T cells in the P. vulgaris-/treated mdr1a mice (Figure 4B).
-/Vehicle-treated mdr1a mice exhibited a 2.5-fold
+
+
increase in the number of PNA B220 germinal center
B cells (Figure 4C) in the cecal tonsil as compared to
WT
vehicle gavaged FVB mice. Remarkably, P. vulgaris
+
+
treatment significantly (P < 0.05) decreased PNA B220
-/germinal center B cells in mdr1a mice (Figure 4C).
+
Together, these data indicate that the expansion CD4 T
+
+
cell and PNA B220 germinal center B cell populations
were significantly lower in the cecal tonsils of P. vulgaris-/treated mdr1a mice.

Impact of the ethanolic extract of P. vulgaris on the
induction of innate chemotactic and pro-inflammatory
cytokines

To further investigate the mechanism(s) related to
improved mucosal homeostasis and the associated
reduction in neutrophils and MPO activity in the colons
-/of P. vulgaris-treated mdr1a mice, serum samples
collected at necropsy were examined for the presence of
chemokines and cytokines. Of those present in the kit,
multiple cytokines/chemokines (Eotaxin, IL-13, IL-15, IL1α, IL-1β, IL-2, IL-3, IL-4, IL-5, LIF, LIX, M-CSF, MCP-1,
MIP-1α, MIP-2, and RANTES) were not detectable in
the serum of any treatment group (data not shown).
However, several analytes were significantly elevated
-/WT
in mdr1a mice compared to FVB mice including
G-CSF, IL-10, CXCL10, KC, CXCL9, and TNF-α (P <
0.01), and IL-9 (P < 0.05) (Table 2). When comparing
-/P. vulgaris extract-treated to vehicle-treated mdr1a
mice, the levels of IL-10 (P < 0.01) and CXCL9 (P <
0.05) and TNF-α (P < 0.05) were significantly lower in
-/the P. vulgaris-treated mdr1a mice (Table 2). For the
remainder of the cytokines/chemokines listed in Table
2, there was a trend for lower amounts in the serum
-/of P. vulgaris-treated mdr1a mice when compared

WJGPT|www.wjgnet.com

P. vulgaris prevents antigenic responses to some
members of the intestinal microbiota

Antibody responses to antigens derived from the gut

230

November 6, 2015|Volume 6|Issue 4|

Haarberg KMK et al . Prunella vulgaris attenuates colitis
Table 2 Assessment of selected cytokines in the serum of mice
Cytokine/chemokine

FVB

WT

vehicle (n = 6)

-/-

G-CSF
GM-CSF
IL-9
IL-10
IL-17
CXCL10
KC
CXCL9
TNFa

-/-

mdr1a vehicle (n = 16)

mdr1a P. vulgaris (n = 13)

9694.0 ± 2563
21.1 ± 11
200.1 ± 38
19.4 ± 4
16 ± 4
724.3 ± 136
527.1 ± 119
3901.0 ± 858
14.8 ± 1

4597.0 ± 1931
1.5 ± 1
117.8 ± 14
4.6 ± 2a,d
1±1
397.2 ± 85
253.4 ± 58
1319.0 ± 277c
9.9 ± 3c

b

140.1 ± 15
ND
77.9 ± 27a
NDb
4±2
8.4 ± 5b
69.5 ± 24b
108.7 ± 37b
9.3 ± 0.1b

Serum samples were collected at the time mice were euthanized and analyzed as described in Materials and
Methods. Average values (pg/mL serum) are shown here ± standard error of the mean except where noted. aP <
0.05, bP < 0.01 compared to mdr1a-/- vehicle with Kruskal-Wallis test with Dunn’s multiple comparisons test. cP <
0.05, dP < 0.01 compared to mdr1a-/- vehicle with unpaired t-test with Welch’s correction. ND: Not detectable; P.
vulgaris: Prunella vulgaris.

Table 3 Attenuation of inflammatory gene expression in mdr1a

-/-

Prunella vulgaris

mice treated orally with an extract from

-/-

a

Fold change compared to vehicle-treated mdr1a mice
Gene
Ccl2
Cxcl1
Cxcl9
Icam1
Il1a
Mmp10
TNFa
Vcam1
Ccl20
Il2

Pathway affiliation
NF-kB, LDL
NF-kB
NF-kB, Jak/Stat
NF-kB, Phospholipase C
NF-kB
NF-kB, Jak/Stat
NF-kB
NF-kB, Phospholipase C, LDL
NF-kB
NF-kB, NFAT, Calcium, PKC

FVB

WT

vehicle healthy

-/-

-/-

mdr1a P. vulgaris healthy

mdr1a P. vulgaris colitic

-3.4
-7.2
-4.2
-1.2
-8.0
-8.5
-2.6
-2.0
-2.0
-2.2

-1.1
-1.0
-1.1
1.8
1.3
1.2
1.2
1.2
1.4
-1.5

-7.3
-11.3
-23.9
-3.2
-13.4
-6.6
-10.2
-3.8
-3.6
-3.7

a

A negative value indicates that there was a lower level of gene expression when compared to the level of gene expression in
vehicle-treated mdr1a-/- mice that developed severe colitis. P. vulgaris: Prunella vulgaris.

deemed unreliable for long-term use in IBD patients,
there is a need for new therapies that may include
[8,9,34]
complementary treatments
. Complementary
and alternative therapy including nutraceuticals hold
realistic potential in treating or supplementing treatment
of inflammatory disorders, as the anti-inflammatory
and antioxidant benefits of plant-derived components
[35-39]
are becoming more extensively characterized
.
P. vulgaris, already popular in Asian medicine, is a
viable candidate for study as a therapeutic agent in the
treatment of IBD as it contains several anti-inflammatory,
immunomodulatory, and antioxidant flavonoids, poly
phenols, and triterpenoids and has no documented toxic
[37,40-44]
side-effects
. In this regard, rosmarinic acid, the
most plentiful phenolic compound found in P. vulgaris,
was found to protect mice against the deleterious effects
associated with sepsis by downregulating inflammatory
genes in the NF-κB pathway including the related pro[45]
inflammatory cytokines TNF-α and IL-6 .
-/The mdr1a mouse model is ideal to use for studies
of potential IBD therapeutics that are relevant to human
-/medicine as mdr1a mice are immunocompetent,
develop spontaneous colitis in the context of a leaky
intestinal epithelium, and exhibit cytokine profiles and

microbiota (e.g., clostridial cluster group XIVa) have
been noted in IBD patients and in murine models of
[31-33]
IBD
. These antibody responses are indicative of a
loss of epithelial integrity and immune tolerance to the
microbiota and do not occur in healthy humans or mice.
-/Pooled serum samples from mdr1a mice treated with P.
vulgaris were evaluated by immunoblot analysis against
antigens (i.e., whole cell sonicate) derived from select
members of the clostridial cluster group XIVa within the
WT
microbiota (Figure 5). As anticipated, sera from FVB
mice did not display antibody reactivity against these
bacterial antigens, suggesting that these mice maintained
immunological tolerance to their gut microbiota.
-/Conversely, sera from vehicle-treated mdr1a mice did
contain antibodies reactive to these bacterial antigens,
indicating a loss of immunologic tolerance to these mem
bers of the microbiota. Sera from P. vulgaris-treated
-/mdr1a mice displayed little to no detectible antibody
response to the three bacterial antigens (Figure 5).

DISCUSSION
As the long term safety and efficacy of current parenteral
therapeutics for IBD are a concern and antibiotics are
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Figure 5 Vehicle-treated mdr1a-/- mice with severe colitic inflammation
developed serum antibody to antigens derived from gut microbiota while
those treated with prunella vulgaris extract do not. Whole cell sonicates of
three separate clostridial species present as part of the intestinal microbiota
(altered Schaedler flora members 356, 500 and 502) were subjected to SDSPAGE. Western blot analysis was performed using sera collected at necropsy.
Antigens in lanes represented in each panel are as follows from left to right:
ASF502, ASF500 and ASF356.
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to attenuate macroscopic lesions associated with the
characteristic severe typhlocolitis observed in this
murine model (Figure 2). In contrast to the vehicle-/-/treated mdr1a mice, ceca of mdr1a mice treated
with a P. vulgaris extract retained normal mucosal
architecture, lacked enlarged lymphoid aggregates, and
retained luminal contents devoid of blood or mucus.
-/Macroscopically, the colons of botanical-treated mdr1a
mice were more similar in appearance to the colons
WT
of the FVB control mice with regard to presence of
formed feces, and lack of grossly visible tissue edema
-/and rigidity (Figure 2). Mdr1a mice treated with P.
vulgaris extract also presented with normal colon lengths
(Figure 2); microscopically, colonic lesions were less
-/attenuated in the botanical extract-treated mdr1a mice
than those present in the cecum (data not shown). The
-/microscopic lesions observed in the ceca of mdr1a mice
treated with P. vulgaris were markedly less severe when
-/compared to those observed for vehicle-treated mdr1a
mice (Table 1). Together, these findings highlight the
differences between colonic and cecal compartments in
terms of the magnitude of the disease. Perhaps these
differences arise from the more dense concentration
of metabolically active microbes in the cecum as
compared to the colon, which may lead to more efficient
metabolism/degradation of the extract and greater
health benefit at more proximal gastrointestinal sites.
Although the etiology of IBD is still ill defined, many
recognize that the inductive phase of colitis involves
a compromised intestinal epithelium and activation
of innate immune responses, including neutrophil
activation, transmigration across the mucosal epithelium,
[3,53-56]
and enzymatic damage to host tissues
. Flavonoids
from licorice have been shown to inhibit neutrophil
infiltration into lung tissue after lipopolysaccharideinduced inflammation and reduce the severity of
associated inflammatory damage to host pulmonary

P. vulgaris
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Figure 4 Evaluation of T cell and B cell subsets in the cecal tonsil of
mdr1a-/- mice treated with prunella vulgaris ethanolic extract. Cecal tonsils
were excised at necropsy, single cell suspensions prepared and labeled for flow
cytometric analysis as described in Materials and Methods. Absolute numbers
of (A) CD4+ T cells; (B) CD8ß+ T cells; and (C) B220+PNA+ germinal center
B cells in the cecal tonsils of mice. aP < 0.05, bP < 0.01 compared to mdr1a-/vehicle as calculated by Kruskal-Wallis test. cP < 0.05 compared to mdr1a-/vehicle as calculated by unpaired t-test. The n for each group is equal to that
noted in Figure 1 and data are representative of two independent experiments.
Vehicle-treated FVBWT mice n = 5-6, vehicle-treated mdr1a-/- mice n = 8-10, P.
vulgaris-treated mdr1a-/- mice n = 5-7.

immune responses similar to those documented in
[30,46-51]
clinical IBD cases
. It was previously demonstrated
that administration of curcumin attenuated mucosal
-/[52]
inflammation in mdr1a mice . In these studies,
similar to previously published studies, onset of clinical
-/disease (e.g., weight loss) in vehicle-treated mdr1a
mice was observed at roughly 10 wk of age (Figure
[30]
1) . In contrast, onset of clinical disease was delayed
by treatment with the P. vulgaris extract; in addition,
-/markedly fewer of the mdr1a mice treated developed
severe clinical disease by 20 wk of age (Figure 1). P.
-/vulgaris treatment of mdr1a mice was also found
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[57]

-/-

tissues . As a group, the mdr1a mice treated with the
P. vulgaris ethanolic extract presented with markedly
less neutrophilic infiltration into the cecal mucosa when
-/compared to vehicle-treated mdr1a mice (Table 1).
Reduction of the neutrophilic infiltrate in these mice
was correlated with less severe microscopic scores and
a significant decrease in tissue levels of MPO activity
(Figures 2 and 3, Table 1). MPO enzymatic activity is a
known correlate to intestinal damage and is often used
as a marker of IBD severity in many animal models of
[58-62]
colitis
.
Since neutrophils are not resident in tissues, cytokine
and chemokine signals produced by epithelial cells and
local macrophages are responsible for the recruitment of
[63,64]
neutrophils into the mucosal tissues
. Homeostatic
production of these innate chemokines is central to
mucosal health, while over-production contributes to
[55,56,65]
the development of severe inflammation in colitis
.
Debate regarding the role of NF-κB activation and
the exacerbated recruitment innate immune cells
in acute intestinal inflammatory models continues,
with some research pointing to a protective effect by
these components and others revealing a deleterious
[23,66-68]
effect
. However, many agree that dysregulation
of NF-κB signaling and the consequent innate cellular
responses are causative factors in the inductive phase
and maintenance of chronic inflammation associated
[69-71]
with human CD and UC
. Pro-inflammatory
mediators induced by activation of NF-κB are abnormally
[72]
upregulated in CD and UC patients . Moreover, it
concludes nuclear translocation of NF-κB in epithelial
cells and local monocytes upregulates production of
pro-inflammatory cytokines and chemokines such as
TNF-α, IL-1β, KC, and CXCL9. These cytokines increase
expression of adhesion molecules (i.e., VCAMs, ICAMs,
and MadCAM ) on endothelial cells, while chemokines
create chemical gradients to attract neutrophils and
[55,64,65,73]
other innate inflammatory cells to sites of injury
.
Others have reported that the ability to regulate or
attenuate cytokine production (e.g., TNF-α, IL-1α, IL1β, IFN-γ) decreases the expression of chemokines
(e.g., IL-8/KC and VEGF) and adhesion molecules on
endothelial cells resulting in amelioration of inflammatory
tissue damage in several disease models, including
[1,45,66,74]
colitis
. The patterns of cytokine and chemokine
production observed in aged-matched, vehicle-treated
-/mdr1a mice in the current study (Table 2) was
[51]
consistent with that previously reported . Serum
-/samples from mdr1a mice treated with the ethanolic
extract of P. vulgaris had lower levels of cytokines that
would contribute to the production of granulocytes
and monocytes (G-CSF and GM-CSF) as well as the
neutrophil chemotactic factor KC (Table 2). Importantly,
treatment with the P. vulgaris extract reduced serum
levels of TNF-α (Table 2), a cytokine known to be a
[75]
key regulator of inflammatory responses in colitis .
These data indicate that P. vulgaris extract reduced the
production of cytokines and chemokines central to the
induction and maintenance of chronic inflammation.
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Activation of the transcription factor NF-κB and the
regulation of its target genes have well documented
links to the chronicity of inflammation associated with
[29,69-71]
IBD
. Recent studies have shown that flavonoids
similar to those identified in P. vulgaris are capable
of downregulating NF-κB and ultimately regulating
the production of innate chemotactic factors and pro[76,77]
inflammatory cytokines
. One such study showed
that the flavonoid luteolin decreased NF-κB expression
-/in the ceca and colons of IL-10 mice, and effectively
[23]
ameliorated spontaneous colitis . Similarly, the
ethanolic extract of P. vulgaris, which is known to contain
[15]
several flavonoids (data not shown) , downregulated
expression of chemokine genes (Ccl2, Cxcl1/KC,
Cxcl9/CXCL9, and Ccl20) and genes involved in the
increased expression of adhesion molecules (VCAM-1,
ICAM, TNFα and IL-1α ) and tissue remodeling to allow
for inflammatory cell transmigration (MMP-10) (Table.
3). All of these genes participate in the activation of or
[78-83]
are regulated by NF-κB
. Based on our findings,
the ethanolic extract of P. vulgaris likely attenuates
-/neutrophil recruitment into the colonic tissues of mdr1a
mice by downregulating genes regulated by NF-κB
signaling. The importance of regulating inflammation
-/in mdr1a mice prior to the onset of clinical disease is
underscored by recent data showing that regulation
-/of inflammatory gene expression is altered in mdr1a
mice and in mice treated with dextran sodium sulfate
[84,85]
(DSS) prior to any histologic signs of inflammation
.
Since defects in gene expression precede inflammation,
prophylactic approaches to control mucosal inflammation
rather than providing therapy at or after the onset of
an inflammatory flare may prove advantageous. In
the current study, therapeutic initiation of P. vulgaris
treatment (i.e., after colitic onset) was ineffective at
reducing the severity of inflammation (data not shown).
This observation supports the current hypothesis that
the ethanolic extract of P. vulgaris modulates innate
inflammatory gene expression, and that effective
treatment should begin prior to the onset of clinical
disease.
In addition to NF-κB signaling and innate immune
activation, adaptive immune responses also play an
integral role in mediating the chronicity and severity of
colitic disease in experimental models and in humans
+
with IBD. In particular, aberrant CD4 T cell responses to
antigens derived from the resident microbiota have been
[31,86]
implicated in the pathogenesis of IBD
. Pretreatment
with the ethanolic extract of P. vulgaris decreased
production of CXCL10 and CXCL9, two proteins that
are induced by IFN-γ and are chemotactic for T cells
[79,87]
(Table 2)
. These chemokines and other cytokines
participate in inflammatory feedback loops that may
be interrupted by treatment with the ethanolic extract
of P. vulgaris. The observation of reduced numbers of
+
+
-/CD4 and CD8 T cells in the cecal tonsils of mdr1a
mice (Figure 4) is consistent with the lower amounts of
CXCL10 and CXCL9 in the serum. There were also lower
-/levels of IL-9 in the serum of mdr1a mice treated with
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inflammatory components but there is limited information regarding the ability
of these extracts to attenuate or prevent inflammation in vivo. Mice that are
deficient in the expression of the multiple drug resistance gene (i.e., mdr1a-/-)
develop spontaneous colitis by 12 to 15 wk of age. As opposed to chemicallyinduced models of colitis, these mice offer a excellent model to assess the
anti-inflammatory capabilities of botanical extracts administered as an oral
formulation.

the ethanolic extract of P. vulgaris (Table 2), a cytokine
+
known to enhance CD4 T cell proliferation and inhibit
[88]
apoptosis . Moreover, the decreased expression of
CXCL9, Ccl2, IL-1α, TNF-α, and Ccl20 genes in extract
-/treated mdr1a mice provides additional evidence
that treatment with P. vulgaris extract impacted the
robustness of the local T cell response (Table 3). CCL20
is strongly chemotactic for immature dendritic cells,
which would mature upon collecting antigen in the
tissues, present that antigen to T cells, and stimulate an
[89]
adaptive immune response .
With respect to the induction of antibody specific to
antigens derived from the resident microbiota, germinal
centers will develop in lymphoid tissue upon B cell
[90]
activation by T dependent antigens . The results of this
+
+
study demonstrated that the number of PNA B220 B
cells present in P. vulgaris-treated mice was significantly
-/less than that detected in the vehicle-treated mdr1a
mice (Figure 4). As a consequence of the attenuated
germinal center B cell response, there was a lack of
antibody production towards bacterial antigens derived
from the resident microbiota in P. vulgaris-treated
-/mdr1a mice (Figure 5). Collectively, these data present
evidence that the ethanolic extract of P. vulgaris acts
-/to maintain mucosal homeostasis in mdr1a mice
by regulating gene expression associated with innate
inflammatory responses and attenuating the activation
of the adaptive immune response.
It has been recently reported that 40% to 50%
of adults suffering with inflammatory bowel disease
or irritable bowel disease utilize complementary and
[34]
alternative medicine to treat their symptoms . Because
of the prevalence at which patients use complementary
approaches to attenuate clinical symptoms, it is critical
to evaluate the efficacy of nutraceuticals in pre-clinical
controlled studies. The work highlighted in this study
indicates that an ethanolic extract derived from P.
vulgaris was safe when administered daily for 14 wk and
markedly attenuated the severity of colitis in mice that
are genetically prone to develop mucosal inflammation.
The health benefits associated with consuming plantderived nutraceuticals are likely associated with the
richness and complexity of anti-inflammatory compounds
present in botanical extracts. There is a need to further
evaluate the underlying mechanism(s) that contributed
to the anti-inflammatory activity of P. vulgaris extracts
in order to provide a basis for their legitimate use as a
prophylactic or supplementary option for the treatment
of IBD and other chronic inflammatory disorders.

Research frontiers

Treatment of inflammatory bowel disease is dominated by the use of drugs and
biologicals that systemically target inflammatory processes. The development
of effective treatment modalities that can be delivered orally and target the
inflammatory response in the gastrointestinal mucosa would reduce the
systemic side-effects observed with other treatment regimen. The studies
presented herein demonstrate that botanical extracts can effectively attenuate
the severity of colitis on a murine model of spontaneous colitis.

Innovations and breakthroughs

This is the first study to demonstrate the oral administration of an ethanolic
extract derived from P. vulgaris can be used to delay the onset of and
ameliorate the severity of spontaneously occurring colitis in mdr1a-deficient
mice.

Applications

It is estimated that 30% to 70% of patients suffering from inflammatory bowel
diseases use some form of complementary and alternative therapy to treat their
symptoms. Many of the parenteral therapies (e.g., steroids, 5-aminosalicylates,
monoclonal antibodies) used to control gastrointestinal inflammation are
associated side-effects. The development of extracts derived from medicinal
plants, such as P. vulgaris, that can be delivered orally and ameliorate
gastrointestinal inflammation may be useful adjunct treatments for IBD patients.

Terminology

Mice lacking the multiple drug resistance (mdr1a) gene fail to produce an
epithelial cell transporter protein (a 107 kDa P-glycoprotein) responsible for
pumping various compounds across the cell membrane. The pathological
lesions and cytokine profiles observed in the colon of mdr1a-deficient mice
resembles that noted in human ulcerative colitis patients.

Peer-review

This is a well written manuscript, investigating the ability of an orallysupplemented P. vulgaris extract to attenuate the clinical symptoms of colitis in
an animal model of spontaneous colitis (mdr1a-/- mice). The authors used valid
methodological approaches to compare the histopathological, biochemical and
immunological profile of the supplemented and control animals, the presentation
of the results was clear and the discussion was thorough.
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